Advertisements

Calciumacetat-Nefro

Quick links to important sections

Calciumacetat-Nefro

Advertisements
Advertisements

Method of action: Mineral, Mineral Supplements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Calciumacetat-Nefro

Property Description
Active ingredient Calcium acetate (INN)
Form Film-coated tablet (Filmtabletten)
Pharmacological class Phosphate binder (PO4 scavenger)
Common use Mineral balance support in kidney patients
Origin Synthetic

What Type of Medicine is Calciumacetat-Nefro?

Calciumacetat-Nefro is a highly specialized, orally administered medicinal product primarily categorized as a phosphate binder, essential for managing mineral balance in the body. Its active component is Calcium acetate (INN), a specific calcium salt derived through a synthetic process, and it is a single active ingredient product. This pharmaceutical classification as a PO4 scavenger defines its unique purpose, distinguishing it from general nutritional supplements. Calcium acetate is used for managing mineral and electrolyte imbalances associated with renal impairment. It serves a role in controlling serum phosphate levels.


Calcium Acetate Composition and Pharmaceutical Form

The medicine is composed solely of the active ingredient, Calcium acetate, which is classified as a mineral and electrolyte replenisher. It is presented most commonly as an oral dosage form, specifically a film-coated tablet (Filmtabletten), which is one of the key factors of the Calciumacetat-Nefro product. The Calcium acetate compound serves as the therapeutic agent, while the remaining solid base forms the tablet structure necessary for easy oral ingestion. Calcium acetate acts to lower serum phosphorus levels in dialysis patients. The core composition and form are intended for reducing the amount of phosphorus in the blood.


What is the General Purpose of a Phosphate Binder?

The general purpose of Calciumacetat-Nefro is to help control the accumulation of phosphorus in the bloodstream, a critical need typically seen in patients with compromised kidney function. It achieves this by employing a simple chemical mechanism: the calcium acetate is highly reactive, binding strongly with the phosphate ions found in food within the digestive tract. This action forms a new, insoluble calcium phosphate complex that cannot be absorbed into the systemic circulation. By removing dietary phosphate from the body via excretion in the stool, the product supports the maintenance of proper overall mineral balance in this specific patient group.

Regulatory References

  1. U.S. National Library of Medicine
Advertisements

What side effects are possible with Calciumacetat-Nefro?

Possible Side Effects and Safety Information

The safety profile for Calciumacetat-Nefro is defined by the potential for the active ingredient, Calcium acetate, to affect systemic calcium levels. The most frequently documented and clinically significant adverse effect across official regulatory sources is Hypercalcemia, an elevation of serum calcium levels, which is classified as very common.

Classification of Adverse Reactions

Adverse reactions are categorized by the system-organ class affected and frequency, based on regulatory standards:

System-Organ Class (SOC) Adverse Reaction Frequency Classification
Metabolism and Nutrition Hypercalcemia Very Common
Gastrointestinal Disorders Nausea, Diarrhea Common
Gastrointestinal Disorders Vomiting Common

Serious Adverse Reactions and Exposure Patterns

Severe manifestations of Hypercalcemia include officially documented symptoms such as confusion, delirium, and, in rare instances, coma. Chronic hypercalcemia is associated with the serious, long-term complications of vascular calcification and soft tissue calcification, which are noted in official labeling. The risk of Hypercalcemia is particularly monitored during the early treatment phase and dosage adjustment. Conversely, calcification risk is associated with long-term exposure.

Population-Specific Safety Constraints

Official regulatory documents note that the safety and effectiveness of Calcium acetate in pediatric patients have not been established. For pregnancy, elevated calcium levels may increase risks to the mother and fetus, including stillbirth and neonatal hypocalcemia. Safety constraints also include warnings against the concomitant use of other calcium-containing products or specific medications like digitalis, as this may contribute to progressive Hypercalcemia.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Calcium acetate (Calciumacetat-Nefro) is primarily documented by regulatory authorities to cause hypercalcemia, resulting from excessive absorption of calcium. The manifestations associated with hypercalcemia include gastrointestinal symptoms such as nausea, vomiting, constipation, and anorexia, alongside systemic signs like muscle weakness and increased thirst (polyuria).


Documented Severe Outcomes and Required Action

Classification Regulatory Statement
Severe Outcomes High levels of hypercalcemia can escalate to severe conditions, including cardiac arrhythmias, acute renal failure, and central nervous system effects such as coma. Chronic overdosage carries a specific risk of soft tissue calcification.
Required Action Seek immediate medical attention or contact emergency services for any suspected or confirmed overdose. Hospital monitoring may be required for evaluation and management.

Management Profile

The regulatory profile states that no specific antidote is known for Calcium acetate overdose. Management is defined as symptomatic and supportive treatment, focusing on measures to reduce serum calcium concentration. This often involves discontinuation of the product and necessary interventions, which may include hemodialysis or peritoneal dialysis for severe, intractable cases, as directed by a healthcare professional. Patients with impaired renal function are noted as having an elevated risk for developing severe hypercalcemia following an overdose.

Advertisements

Therapeutic Uses of Calciumacetat-Nefro

What Calciumacetat-Nefro Treats: Main Uses and Benefits

Calciumacetat-Nefro is a highly specialized therapeutic agent that is considered relevant for managing mineral balance in patients with advanced Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD). It is commonly used when symptoms related to systemic imbalance interfere with daily functioning and create noticeable physiological strain. The primary conditions it helps manage include hyperphosphatemia, the risk of vascular calcification, and the manifestation of renal osteodystrophy.


Key Therapeutic Focus

This medication supports the body by addressing the high phosphate load that results from compromised kidney function. The drug's use in this domain supports the easing of distressing uremic manifestations. This supportive relief helps patients cope more steadily with symptom fluctuations. The medication is applied in situations involving certain irritative states, such as severe, persistent uremic pruritus (chronic itching) and may also support patients during episodes of heightened discomfort from neuromuscular symptoms like muscle cramps or paresthesias.

Quick Fact: Relief for Chronic Itching
Managing phosphate levels with this medicine can help ease the intense, chronic discomfort of uremic pruritus, which is a common symptom related to systemic imbalance in CKD.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Population Eligibility for Calciumacetat-Nefro

This section outlines the official population eligibility rules for Calciumacetat-Nefro (Calcium Acetate) as defined by governmental regulatory documents.


Absolute Contraindications

Use of this medicine is formally prohibited in patients diagnosed with hypercalcemia (abnormally high calcium levels in the blood) and in individuals with a known hypersensitivity or allergy to calcium acetate or any other component of the specific product. Some regulatory bodies also define use as contraindicated in patients with hypercalciuria and nephrolithiasis (kidney stones).


Age-Specific Eligibility

Age Group Regulatory Statement
Pediatric Use (Children/Adolescents) Safety and effectiveness have not been established in this patient population.
Geriatric Use (65 and Over) While no overall difference in effectiveness was observed, caution is advised due to the greater likelihood of decreased organ function in this age group.

Conditional Use and Restrictions

Eligibility is restricted for patients taking digitalis (cardiac glycosides); use in this group requires close monitoring due to the risk of cardiac arrhythmias. For women who are pregnant, the medicine is classified as Category C and should be administered only if clearly needed, with mandatory monitoring of maternal serum calcium levels. Use during lactation (breastfeeding) is generally not expected to harm an infant, provided maternal calcium levels are appropriately monitored.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Calciumacetat-Nefro primarily interacts with other orally administered medicines by altering their absorption in the digestive tract. This physicochemical binding can lead to a documented reduction in the systemic exposure (bioavailability) of co-administered drugs. Regulatory information establishes mandatory timing separation requirements for several drug classes to mitigate this effect.

Timing Separation Requirements

Interacting Substance Administration Timing Restriction
Fluoroquinolone Antibiotics (e.g., Ciprofloxacin) Must be taken at least two hours before or six hours after calcium acetate.
Levothyroxine (Thyroid Products) Must be taken at least four hours before or four hours after calcium acetate.
Tetracycline Antibiotics Must be taken at least one hour before calcium acetate.

Combination and Pharmacodynamic Restrictions

Beyond absorption effects, the potential for high blood calcium (hypercalcemia) from treatment establishes specific pharmacodynamic cautions. The use of calcium acetate is formally contraindicated in patients with pre-existing hypercalcemia. Coadministration with cardiac glycosides (e.g., Digoxin) must be approached with regulatory caution, as hypercalcemia may officially aggravate digitalis toxicity.

Furthermore, the combination with calcium supplements or Vitamin D metabolites is officially restricted due to the increased risk of severe hypercalcemia. Regulatory documents also specify that calcium acetate is intended to be taken with meals, which relates to its function as a phosphate binder.

Advertisements

Mechanism of Action

The mechanism of Calciumacetat-Nefro is based on a localized chemical process that restricts the body's absorption of an ingested nutrient, with no direct interaction with systemic receptors or enzymes.


Chemical Scavenging and Local Inhibition of Absorption

The drug's action begins in the gastrointestinal tract, where it utilizes Calcium ions ( Ca^2+), liberated from the salt, to chemically bind with dietary phosphate ions ( PO4). This high-affinity binding reaction forms an Insoluble Calcium Phosphate Complex that cannot be transported across the intestinal wall. By physically sequestering the phosphate and inhibiting its absorption pathway, the drug ensures that the PO4 is diverted for excretion via the stool.


Indirect Modulation of Systemic Mineral Homeostasis

By reducing the systemic phosphate load entering the circulation, the drug initiates a physiological cascade that leads to a decrease in serum phosphate concentration. This lowering effect indirectly acts on the mineral regulatory axis—the feedback loop governing calcium, phosphate, and Parathyroid Hormone (PTH). This secondary influence contributes to mineral balance regulation and attenuates the stimulus for Parathyroid Hormone (PTH) secretion.

Advertisements

Dosage and Administration Information

How to Use Calciumacetat-Nefro: Official Administration Guidelines

Calciumacetat-Nefro is intended for oral administration as a long-term therapy for chronic mineral balance management. Its usage is strictly governed by the timing of dietary intake, requiring the medicine to be taken concurrently with meals or immediately after the start of a snack to ensure the medicine is present to bind phosphate in the gastrointestinal tract.


Labeled Administration Principles

Feature Official Regulatory Guideline
Route & Form Oral administration; commonly available as tablets, capsules (667 mg strength), or solution.
Standard Dosing The typical starting dose for adults is two units taken with each meal. The maintenance range commonly involves three to four units with each meal.
Dose Titration Dosing is adjusted gradually based on specific serum phosphorus levels. Dose changes should occur no more frequently than every two to three weeks.
Missed Dose If a dose is missed, skip the missed dose and take the next scheduled dose with the next meal; a double dose should not be taken to compensate.

Procedural and Population Constraints

The dosage form should generally be swallowed whole as directed by the label; liquid forms require measurement using a dedicated device. Administration may require timing separation from other oral medications, specifically recommending that other drugs be taken at least one hour before or three hours after the phosphate binder. Regarding specific populations, safety and efficacy have not been established for use in pediatric patients (under 18 years of age).

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Calciumacetat-Nefro

Evidence for Phosphate Control in Dialysis Patients (ESRD)

Research has explored calcium acetate in patients with high phosphate levels who are receiving maintenance hemodialysis or peritoneal dialysis, primarily through Randomized Controlled Trials (RCTs). These studies are designed to explore different treatment approaches, tracking surrogate biomarkers like serum phosphorus concentration and intact parathyroid hormone (iPTH). Controlled trials described consistent measurements of lower serum phosphorus concentrations in the group receiving calcium acetate when compared to the placebo group. Comparative research has also explored differences in measured serum phosphorus when calcium acetate was compared to non-calcium based treatments.

Studies Examining Biomarkers in Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)

Research has also explored calcium acetate in adults with advanced Chronic Kidney Disease (CKD) who are not yet receiving dialysis. These short-term RCTs track changes in serum phosphorus and iPTH levels. These trials reported measurements of lower serum phosphorus concentrations in the intervention group over the study period compared to the placebo group. The follow-up durations were limited, often covering only about 12 weeks.

What Is Still Uncertain in the Research Record

The majority of evidence is focused on short-term follow-up. Evidence regarding calcium acetate’s impact on hard endpoints, such as all-cause mortality, cardiovascular events, or fracture rates over many years, is not well established through large, dedicated, long-term RCTs. A key uncertainty relates to whether achieving target phosphate levels with calcium acetate translates directly into changes in long-term clinical outcomes. Furthermore, comparative evidence concerning which class of binder provides different long-term survival outcomes has shown mixed findings across different studies.

Key Studies & References Calcium Acetate: Drug Information (Hyperphosphatemia Use)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Calciumacetat-Nefro (FAQ)


Q: How quickly can someone expect the drug to start working?

This medicine is designed to work immediately in the digestive tract by binding to phosphate in food. Official product information indicates that the dose is typically adjusted every two to three weeks based on monitoring blood phosphorus levels. Therefore, while the initial binding action is immediate, achieving the target therapeutic effect on blood chemistry may require gradual dose adjustments over time.


Q: Can Calciumacetat-Nefro cause weight gain or weight loss?

Official reports on adverse effects have noted occurrences of loss of appetite and weight loss. These symptoms are sometimes linked to the most common side effect of the medicine, which is hypercalcemia (high blood calcium levels). Reports of weight gain are not frequently noted in official documentation. Persistent or concerning symptoms should be discussed with a healthcare provider.


Q: Is a headache a common side effect of Calciumacetat-Nefro?

Headache has been noted in post-approval reports of adverse events. It can also be a potential sign of hypercalcemia, which is the most frequent and clinically significant side effect of the medicine. Persistent or concerning symptoms should be discussed with a healthcare provider.


Q: Is it okay to take antacids while using Calciumacetat-Nefro?

Regulatory documents restrict the co-administration of calcium-containing products, including calcium-based antacids, while on this medication. Combining them may significantly increase the risk of hypercalcemia (abnormally high blood calcium levels). This caution is in place because the medicine itself adds calcium to the body.


Q: Can Calciumacetat-Nefro cause constipation, and is that normal?

Constipation is a reported adverse reaction noted in regulatory documentation. Furthermore, it is also listed as a potential manifestation of mild hypercalcemia, the most common side effect of this medicine. The occurrence of constipation is listed as a documented possible adverse effect.


Q: Can people with high blood pressure use Calciumacetat-Nefro?

Official contraindications are focused on pre-existing conditions like hypercalcemia and known allergy/hypersensitivity to the drug. High blood pressure (hypertension) is not explicitly listed as a contraindication in official regulatory documents.


Q: Does taking Calciumacetat-Nefro affect Vitamin D levels?

Official documents note that the use of this medicine is closely tied to the body’s mineral regulatory balance, which involves Vitamin D. If high blood calcium levels (hypercalcemia) develop, regulatory guidelines state that decreasing or stopping Vitamin D therapy may be recommended by a doctor.


Q: Is the effect of the drug immediate, or does it build up over time?

The mechanism of this medicine is based on a direct, local action—binding phosphate in the gut immediately after ingestion. However, the dose is adjusted gradually, sometimes every two to three weeks, based on blood test results. This gradual adjustment helps in achieving and maintaining the target level of phosphorus in the blood.


Q: Is it possible to be allergic to Calciumacetat-Nefro?

Yes. Official documents state that a known hypersensitivity or allergy to calcium acetate or any component of the product is an absolute contraindication for use. Regulatory reports have also included isolated cases of general allergic reactions (such as pruritus, or severe itching).


Q: Do I need a prescription to get Calciumacetat-Nefro?

Yes, regulatory labeling from authorities like the FDA classifies this product as a Human Prescription Drug. This means it is available only with a prescription from a licensed healthcare provider.


Q: Can I stop taking Calciumacetat-Nefro if I feel better?

This medication is intended for long-term use as part of managing chronic mineral balance. Official guidelines indicate that management, including changes to the dose or stopping therapy, is based on specific laboratory test results (like serum phosphorus levels), and not solely on a patient's subjective feeling of wellness.


Q: Is this medicine used for any condition other than kidney-related issues?

According to official drug labeling, this medicine is indicated solely for a specific purpose. That purpose is the reduction of serum phosphorus levels in patients who have end-stage renal disease (ESRD), which is a severe form of kidney-related issue.


Q: Are there any mental or mood-related side effects linked to this medicine?

Official documents have noted mental- or mood-related adverse effects such as confusion, delirium, and depression. These symptoms are associated with the more severe manifestations of hypercalcemia (high blood calcium levels), which is a key potential side effect of the medicine.


Q: Is Calciumacetat-Nefro considered a medication for bone health?

The primary purpose of this medicine is its classification as a phosphate binder to manage mineral levels in the blood. However, by lowering blood phosphate, it indirectly influences mineral regulatory hormones that are fundamentally involved in maintaining overall bone health.


Q: Can taking this medicine make me feel tired or dizzy?

Reports have noted side effects that include dizziness, weakness, and unusual tiredness. These effects are often associated with the presence of hypercalcemia (high blood calcium levels), which is the most frequent adverse reaction to the medicine.


Q: What do official sources say about the safety profile of Calciumacetat-Nefro?

The safety profile is predominantly defined by the most frequent and clinically significant adverse effect, which is Hypercalcemia (high blood calcium levels). Regulatory documents classify this risk as very common. Other frequently reported adverse events include nausea, diarrhea, and vomiting.


Q: Are there different strengths or forms of Calciumacetat-Nefro?

Official documents note that calcium acetate is commonly available in several forms and strengths. These typically include a 667 mg tablet or capsule and may also be available in a liquid solution.


Q: Is it safe to drive after taking Calciumacetat-Nefro?

The regulatory side effect profile includes reports of dizziness and confusion, especially when hypercalcemia occurs. Because these symptoms could potentially affect one's attention, patients are generally advised to be aware of their reaction to the medication before driving or operating machinery.


Q: Does this medicine cause a dry mouth?

Dry mouth has been noted in official reports among the post-approval adverse events. Like some other symptoms, dry mouth can be a potential indication of hypercalcemia (high blood calcium levels), which is a common side effect of the medicine.


Q: Is there a possibility of developing a calcium buildup in the body while on this treatment?

Yes, regulatory warnings state that chronic hypercalcemia (high blood calcium levels) is a risk associated with this treatment. This condition is linked to serious, long-term complications such as the development of vascular calcification and soft tissue calcification.


Q: How is the effectiveness of Calciumacetat-Nefro measured by doctors?

The effectiveness of the medication is primarily monitored by tracking specific laboratory results. Regulatory documents indicate that the dosage is based on specific serum phosphorus levels in the blood, which guides ongoing management.

Advertisements

How should Calciumacetat-Nefro be stored and disposed of?

Storage Conditions

Calciumacetat-Nefro tablets must be stored at a temperature that does not exceed 30 C, as specified in the official labeling. To maintain the medicine's stability, it must be stored in the original packaging and kept protected from light and moisture. Use of the medicine is restricted after the expiry date printed on the carton and blister pack.

Child Safety and Disposal

It is mandatory to keep this medicine out of the sight and reach of children.

For disposal, unused or expired tablets must not be thrown into wastewater (e.g., flushed down a toilet or poured down a sink). To ensure proper environmental protection, regulatory instructions require users to ask the pharmacist for guidance on how to dispose of the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calciumacetat-Nefro found in:

A-Z Index: